Cited by 707Cardiovascular Health and Risk FactorsLipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics

Kavey, Rae-Ellen W., Allada, Vivek, Daniels, Stephen R., Hayman, Laura L., McCrindle, Brian W., Newburger, Jane W., Parekh, Rulan S., Steinberger, Julia·2006·Circulation

Abstract

Although for most children the process of atherosclerosis is subclinical, dramatically accelerated atherosclerosis occurs in some pediatric disease states, with clinical coronary events occurring in childhood and very early adult life. As with most scientific statements about children and the future risk for cardiovascular disease, there are no randomized trials documenting the effects of risk reduction on hard clinical outcomes. A growing body of literature, however, identifies the importance of premature cardiovascular disease in the course of certain pediatric diagnoses and addresses the response to risk factor reduction. For this scientific statement, a panel of experts reviewed what is known about very premature cardiovascular disease in 8 high-risk pediatric diagnoses and, from the science base, developed practical recommendations for management of cardiovascular risk.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.106.179568

Cites

399 of 399 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Data suggest that care for type 1 diabetes has improved, as evidenced by reduced rates of microvascular disease in past decades, whereas data on cardiovascular disease suggest substantially less progress in reducing macrovascular disease rates.

    “Furthermore, there are data to suggest that care for T1D has improved as evidenced by reduced rates of microvascular disease in the past decades109–111, whereas data on CVD suggest that substantially less progress has been made in reduction of macrovascular disease rates111–113.”

    From Epidemiology of type 1 diabetes (2010) · cites this paper as [111]

  • The AHA categorizes type 1 children in the highest tier for cardiovascular risk and recommends both lifestyle and pharmacologic treatment for those with elevated LDL cholesterol levels.

    “the AHA categorizes type 1 children in the highest tier for cardiovascular risk and recommends both lifestyle and pharmacologic treatment for those with elevated LDL cholesterol levels (285,286).”

    From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [285]

Cites

2 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J.
Affiliations
National Heart, Lung, and Blood Institute (US)
Venue
Circulation
Published
2006-12-12
Volume
114
Issue
24
Pages
2710-2738
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2166512947
Cited by
707
References
399
Citations by year
2026: 6 · 2025: 18 · 2024: 11 · 2023: 24 · 2022: 37 · 2021: 22 · 2020: 37 · 2019: 22 · 2018: 30 · 2017: 27 · 2016: 36 · 2015: 52 · 2014: 48 · 2013: 56 · 2012: 57
FWCI
6.12
Type
journal article
Language
en
Open access
closed
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
cardiovascular risk reduction, pediatric atherosclerosis, premature cardiovascular disease, risk factor control, cardiovascular disease prevention, clinical guidelines
MeSH terms
Arthritis, Rheumatoid, Cardiovascular Diseases, Child, Chronic Disease, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Heart Defects, Congenital, Humans, Hyperlipoproteinemia Type II, Kidney Diseases, Lupus Erythematosus, Systemic, Mucocutaneous Lymph Node Syndrome, Neoplasms, Risk Factors, Heart Transplantation, Evidence-Based Medicine, Risk Reduction Behavior, Diabetes Complications, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review